journal article·2025-12-24

Injectable Hierarchical Microsphere-Hydrogel System for the Sustained Release of Bupivacaine and Celecoxib in Long-Acting Analgesia

Bo Lu, Junhui Yang, Yingying Lv, Fan Fan, Qien Zhao, Xiaowei Chen, Junping Chen, Lei Jiang, Jiantao Zhang

ACS Applied Materials & Interfaces· Volume 17· Issue 51
Publisher page

Abstract

Postoperative pain is a common issue after surgical procedures. While peripheral nerve blocks are an effective strategy for postoperative pain management, local anesthetics, although offering potent analgesia with minimal systemic side effects, are limited by their short half-life and rapid clearance. In this study, we developed an injectable microsphere/hydrogel (MS/Gel) composite designed to provide prolonged local anesthesia. The composite consists of poly(lactic- co -glycolic acid) (PLGA) microspheres coloaded with bupivacaine (Bup) and celecoxib (Cel) via electrostatic spraying and incorporated into a thermosensitive gel matrix composed of poloxamer 407 (P407) and hyaluronic acid (HA). The MS/Gel composite exhibited excellent injectability, uniform microsphere distribution, and a biphasic sustained-release profile, significantly reducing the burst release. In vitro evaluations demonstrated that drug release was extended to more than 10 days. Furthermore, in a rat sciatic nerve block model, the MS/Gel significantly prolonged both mechanical and thermal pain thresholds for up to 48 h. Biocompatibility assessments confirmed good cytocompatibility, biodegradability, lack of neurotoxicity, and only a mild, reversible inflammatory response. Overall, the MS/Gel composite presents a promising strategy for postoperative pain management, providing a safe and effective sustained-release system for long-acting local anesthesia.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Anesthesia and Pain Management · Pain Mechanisms and Treatments · Pain Management and Opioid Use

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Ningbo No. 2 Hospital

Laboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Materials Technology and Engineering

Chinese Academy of Sciences

Cixi Institute of Biomedical Engineering

Health Science Center

Ningbo University

Zhejiang Key Laboratory of Biopharmaceutical Contact Materials

Funding

Natural Science Foundation of Ningbo Municipality · National Key Research and Development Program of China · China Postdoctoral Science Foundation · Ningbo Municipal Bureau of Science and Technology

References (48)

Show source-provided references
1. 10.1016/j.aat.2015.07.00310.1016/j.aat.2015.07.003 ↗
2. 10.1016/j.jiec.2019.02.02810.1016/j.jiec.2019.02.028 ↗
3. 10.1021/acsami.4c0788310.1021/acsami.4c07883 ↗
4. 10.1016/S0140-6736(19)30352-610.1016/S0140-6736(19)30352-6 ↗
5. 10.1016/j.ygyno.2022.06.00610.1016/j.ygyno.2022.06.006 ↗
6. 10.1016/j.clineuro.2020.10612510.1016/j.clineuro.2020.106125 ↗
7. 10.1016/j.jclinane.2022.11091810.1016/j.jclinane.2022.110918 ↗
8. 10.1016/j.molliq.2021.11652610.1016/j.molliq.2021.116526 ↗
9. 10.1080/10717544.2021.202370210.1080/10717544.2021.2023702 ↗
10. 10.2147/DDDT.S41705110.2147/DDDT.S417051 ↗
11. 10.3389/fimmu.2025.155779010.3389/fimmu.2025.1557790 ↗
12. 10.3390/ph1404036010.3390/ph14040360 ↗
13. 10.1007/s10787-025-01686-110.1007/s10787-025-01686-1 ↗
14. 10.1021/acs.biomac.3c0117910.1021/acs.biomac.3c01179 ↗
15. 10.1136/rapm-2023-10468110.1136/rapm-2023-104681 ↗
16. 10.1021/acsapm.2c0225610.1021/acsapm.2c02256 ↗
17. 10.1080/10601325.2024.235555210.1080/10601325.2024.2355552 ↗
18. 10.1002/pen.2720010.1002/pen.27200 ↗
19. 10.1021/acsami.8b0439410.1021/acsami.8b04394 ↗
20. 10.1016/j.msec.2020.11070210.1016/j.msec.2020.110702 ↗
21. 10.1021/bm201170h10.1021/bm201170h ↗
22. 10.1177/155932582092955510.1177/1559325820929555 ↗
23. 10.1002/adhm.20200134110.1002/adhm.202001341 ↗
24. 10.1016/j.msec.2015.06.01810.1016/j.msec.2015.06.018 ↗
25. 10.1021/acsbiomaterials.8b0110710.1021/acsbiomaterials.8b01107 ↗
26. 10.1016/j.ijpharm.2023.12279310.1016/j.ijpharm.2023.122793 ↗
27. 10.1016/j.ijbiomac.2022.06.21010.1016/j.ijbiomac.2022.06.210 ↗
28. 10.1016/j.ijpharm.2022.12255110.1016/j.ijpharm.2022.122551 ↗
29. 10.1016/j.biomaterials.2023.12212910.1016/j.biomaterials.2023.122129 ↗
30. 10.1038/s41467-020-16177-w10.1038/s41467-020-16177-w ↗
31. 10.7150/thno.7484510.7150/thno.74845 ↗
32. 10.1016/j.mtbio.2023.10071210.1016/j.mtbio.2023.100712 ↗
33. 10.1126/sciadv.abk242510.1126/sciadv.abk2425 ↗
34. 10.1016/j.xpro.2022.10175610.1016/j.xpro.2022.101756 ↗
35. 10.21769/BioProtoc.250610.21769/BioProtoc.2506 ↗
36. 10.1016/j.ijbiomac.2025.14284510.1016/j.ijbiomac.2025.142845 ↗
37. 10.1016/j.ejpb.2022.09.02210.1016/j.ejpb.2022.09.022 ↗
38. 10.1016/j.ijpharm.2021.12074810.1016/j.ijpharm.2021.120748 ↗
39. 10.1016/j.jconrel.2025.01.02810.1016/j.jconrel.2025.01.028 ↗
40. 10.3390/ijms2103109310.3390/ijms21031093 ↗
41. 10.3390/pharmaceutics1503073010.3390/pharmaceutics15030730 ↗
42. 10.1016/j.ejps.2019.10502610.1016/j.ejps.2019.105026 ↗
43. 10.1002/cben.20230002710.1002/cben.202300027 ↗
44. 10.1093/bja/aep23610.1093/bja/aep236 ↗
45. 10.1016/j.bja.2017.11.10310.1016/j.bja.2017.11.103 ↗
46. 10.1182/blood-2018-11-88434610.1182/blood-2018-11-884346 ↗
47. 10.1080/17512433.2022.213222710.1080/17512433.2022.2132227 ↗
48. 10.1016/j.actbio.2025.04.03310.1016/j.actbio.2025.04.033 ↗